Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Add To Watchlist

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > Great Management - Grant Saves Shareholder Dilution Again!!

View:

Post by PeptidePete on Aug 05, 2024 12:34pm

Great Management - Grant Saves Shareholder Dilution Again!!

The recent PONTIAC trial grant saves shareholders 1,268,000 shares in dilution. Since 2018 the company has only performed 4 financings, all Non Brokered with No Warrants.

July 29, 2024 (Unknown) - $1.50 per common share for net proceeds of $600,000 CAD
Dec 23, 2020 (One Placee) - $1.50 per common share for net proceeds of $645,000 CAD
June 30, 2020 (Two Placees) - $1.50 per common share for net proceeds of $1,350,000 CAD
Feb 2, 2018 (One Placee) - $ .50 per common share for net proceeds of $1,250,000 CAD

Arch Shareholders have raised $3,845,000 from the markets while $12,750,000 in grant funding from the Canadian Government. This recent PONTIAC trial grant adds an additional $1,900,000 progressing Cilastatin in a Phase II clinical trial.

142